Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6375876 | 0.95 | L3MBTL1 (0.36) | KDM4ETDP1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL25180363 | 0.80 | MAPT (0.31) | MAPTKMT2AMEN1 | |
| SCHEMBL16549482 | 0.76 | ALDH1A1 (0.39) | LMNARECQLSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL4364410 | 0.75 | KDM4E (0.41) | KDM4ETDP1L3MBTL1RECQLMAPT | |
| SCHEMBL12299798 | 0.75 | ALDH1A1 (0.48) | KDM4ETDP1RECQLMAPTALDH1A1 | |
| SCHEMBL8257439 | 0.75 | SLC6A4 (0.42) | KDM4ETDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL264987 | 0.74 | ALDH1A1 (0.46) | KDM4ELMNAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL29466255 | 0.74 | ALDH1A1 (0.46) | KDM4ELMNAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL14478367 | 0.73 | POLB (0.40) | KDM4ETDP1LMNAL3MBTL1MAPT | |
| SCHEMBL22219086 | 0.73 | ALDH1A1 (0.41) | KDM4ETDP1LMNAL3MBTL1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | KDM4E 1078/4885TDP1 163/4885LMNA 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.